Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 68Ga-DOTANOC PET/computed tomography in articular manifestation of rheumatoid arthritis
- 17 January 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 43 (4) , 428-432
Abstract
Objective: Tc-99m methyl diphosphonate (MDP) bone scintigraphy is used to assess disease activity in rheumatoid arthritis (RA). Somatostatin receptor (SSTR) expression in RA has been reported previously. SSTR-based PET/computed tomography (CT) may be superior to bone scintigraphy to know disease extent and in locating inflammatory joints that can be further targeted with peptide receptor radionuclide therapy thereby opening up new theranostic avenues. Based on these facts, the present study was designed to compare Tc-99m MDP bone scintigraphy and Ga-68 DOTANOC PET/CT in patients with RA. Materials and methods: Patients with a clinical diagnosis of RA were injected with 111–185 MBq of Ga-68 DOTANOC and 740 MBq of Tc-99m MDP intravenously. Images were acquired 30–45 min postinjection for Ga-68 DOTANOC on dedicated PET/CT scanners. Triple-phase bone scans were acquired on a dual-head gamma camera. PET/CT and MDP scan images were visually assessed by two experienced nuclear medicine physicians. Results: Nineteen patients (16 women and 3 men) with a clinical diagnosis of RA were included in the study. Clinically, 196 joints in these 19 patients were diagnosed positive for RA. Of these 196 joints, Tc-99m MDP uptake was seen in 157 joints (80%). On Ga-68 DOTANOC scan, tracer uptake was seen in 151 of 196 joints (77%) with a lesion to background ratio of at least 2 in most of the joints. Conclusion: Ga-68 DOTANOC is equally good as an MDP scan for detection of RA with the added advantage of being used as a theranostic modality. However, further evaluation with a larger sample size and joint-to-joint comparison is warranted.Keywords
This publication has 11 references indexed in Scilit:
- Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic reviewEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and OncologyJournal of Clinical Medicine, 2019
- Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patientsTheranostics, 2018
- Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren’s syndrome treated with Infliximab: a pilot studyEJNMMI Research, 2016
- Literature review of rheumatoid arthritis in IndiaInternational Journal of Rheumatic Diseases, 2015
- Role of Somatostatin Analogues in the Treatment of Neuroendocrine TumorsJournal of the National Comprehensive Cancer Network, 2015
- 68Ga-labeled DOTA-Peptides and 68Ga-labeled Radiopharmaceuticals for Positron Emission Tomography: Current Status of Research, Clinical Applications, and Future PerspectivesSeminars in Nuclear Medicine, 2011
- Vascular somatostatin receptors in synovium from patients with rheumatoid arthritisEuropean Journal of Pharmacology, 1994
- Somatostatin receptor imaging. the presence of somatostatin receptors in rheumatoid arthritisArthritis & Rheumatism, 1994